Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo

Phase 2

Mayo Clinic
University of Virginia

AstraZeneca